281
Coadministration of 200 mg bid voriconazole with 400 mg (or higher) qd efavirenz is contraindicated due to the clinically significant effect of efavirenz on voriconazole pharmacokinetics.
 clinically significant effect: Effect; Coadministration of 200 mg bid voriconazole with 400 mg (or higher) qd efavirenz: Treatment; efavirenz on voriconazole: Treatment; 200 mg: Treatment.Dosage; 400 mg: Treatment.Dosage; voriconazole: Treatment.Drug; efavirenz: Treatment.Drug; efavirenz: Treatment.Drug; voriconazole: Treatment.Drug; voriconazole: Combination.Drug; efavirenz: Combination.Drug
Given event type and trigger, please tell me the arguments of all the listed option. Output format is "name1: role1; name2: role2". 
Event type: adverse event 
  Option: Treatment.Freq, Subject.Population, Combination.Drug, Subject.Gender, Treatment.Duration, Subject, Effect, Treatment, Treatment.Disorder, Subject.Disorder, Treatment.Route, Subject.Race, Treatment.Time_elapsed, Treatment.Dosage, Subject.Age, Treatment.Drug 
Text: {0} 
Answer:
 clinically significant effect: Effect; Coadministration of 200 mg bid voriconazole with 400 mg (or higher) qd efavirenz: Treatment; efavirenz on voriconazole: Treatment; 200 mg: Treatment.Dosage; 400 mg: Treatment.Dosage; voriconazole: Treatment.Drug; efavirenz: Treatment.Drug; efavirenz: Treatment.Drug; voriconazole: Treatment.Drug; voriconazole: Combination.Drug; efavirenz: Combination.Drug